Aktienanalyse zu Compugen Ltd (CGEN)CGENCompugen Ltd

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).

Compugen Ltd (CGEN) appears to be a good buy right now due to its current price of $2.60, which is significantly below the analyst price target of $6, indicating a potential upside of approximately 130%. Additionally, the company has a strong cash position of approximately $134.9 million, which is expected to fund operations into 2029, providing stability for long-term investors. However, a key risk is the recent insider selling activity, which has increased by 177.02%, suggesting potential concerns among insiders about the company's near-term performance.

2 analysts cover CGEN: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 4.00.